ClinicalTrials.gg

Bronchiectasis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 404 studies for Bronchiectasis across more than 10 countries. 125 are recruiting or about to start. 297 of them are mainly about Bronchiectasis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Kartagener Syndrome too: 425 studies, 129 open.

Status

Completed
163
Recruiting
93
Status unknown
71
Not yet recruiting
28
Terminated
26
Active, not recruiting
13

Phase

Phase 2
48
Phase 4
37
Phase 3
35
Phase 1
26
Early Phase 1
2

Where

China
84
United Kingdom
73
United States
65
Spain
39
Turkey
36
Italy
30

Who develops what

Add Bronchiectasis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 13 with this as their studies’ main aim; 3 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, AstraZeneca and Boehringer Ingelheim here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
florensocatib☆ Track2 live phase-3 studies: NCT07616375, NCT06660992Haisco Pharmaceutical Group Co., Ltd.
verducatib☆ Track2 live phase-3 studies: NCT06872892, NCT07915219Boehringer Ingelheim
florensocatib☆ Track1 live phase-3 study: NCT07577804Chiesi Farmaceutici S.p.A.

The 3 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Nov 2026 est.florensocatib · Haisco Pharmaceutical Group Co., Ltd. · Phase 3 main aimNCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis — primary endpoint: Frequency of pulmonary exacerbations · 669 enrolled
  • 31 Mar 2027 est.verducatib · Boehringer Ingelheim · Phase 2 main aimNCT05846230 Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine — primary endpoint: Occurrence of treatment-emergent adverse events (TEAEs) · 268 enrolled
  • 31 Mar 2027 est.ALX1 · Vast Therapeutics · Phase 2 main aimNCT07731919 Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis — primary endpoint: Proportion of participants with a metHb value ≥ 5% per dose level · 28 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Bronchiectasis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Bronchodilators 2 open

Coming up

51studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger. 12 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 26 (28%) take healthy volunteers.

Recruiting studies that take each age, of 93
AgeWomenMen
109 (10%)9 (10%)
1884 (90%)84 (90%)
3087 (94%)87 (94%)
4089 (96%)89 (96%)
5088 (95%)88 (95%)
6587 (94%)87 (94%)
7581 (87%)81 (87%)
8568 (73%)68 (73%)

Across all 404 studies, recruiting or not: 23% stop at 75 or younger and 15% at 65; 15% take children; <1% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Bronchiectasis studies take

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 224 mo15–32 · 24 studies——
Interventional, no phase20 mo10–59 · 78 studies—20 mo10–67 · 72 studies
Observational34 mo12–… · 61 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 404. Browse all 404 → or search them.